Beam Q1 net loss $96.5M ($1.33/sh); BEACON trial advancing, BEAM-201 on track

Beam Therapeutics Inc.

2023-Q1 EPS reported -$1.33 revenue$24,208,000

Net loss $96.5M ($1.33/sh) vs $69.2M ($1.01/sh) YoY; R&D spend up to $99.6M.
Cash, equivalents and securities $1.1B; runway expected at least into 2025.
BEACON trial sentinel cohort: first patient withdrawn (non-medical), 2 enrolled; full cohort expected in 2023.
BEAM-201 Phase 1/2 for T-ALL/T-LL on track to dose first patient by mid-2023.
Gopi Shanker appointed CSO; regulatory filings for BEAM-301 (late 2023/early 2024) and BEAM-302 (early 2024).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Beam Therapeutics Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $96.5 million for the first quarter of 2023, or $1.33 per share, EPS $1.33 per share.

Period: the quarter ended March 31, 2023
Net income: Net loss was $96.5 million for the first quarter of 2023, or $1.33 per share
EPS: $1.33 per share
Result: reported results

Exact text from the filing

Net loss was $96.5 million for the first quarter of 2023, or $1.33 per share, compared to $69.2 million for the first quarter of 2022, or $1.01 per share.

View on SEC.gov

Browse all earnings releases →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.